» Authors » Samuel Volchenboum

Samuel Volchenboum

Explore the profile of Samuel Volchenboum including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 94
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Espinoza A, Bagatell R, McHugh K, Naranjo A, Van Ryn C, Rojas Y, et al.
Pediatr Blood Cancer . 2024 Jul; 71(10):e31218. PMID: 39072986
Background: Image-defined risk factors (IDRFs) were promulgated for predicting the feasibility and safety of complete primary tumor resection in children with neuroblastoma (NB). There is limited understanding of the impact...
2.
Tilmon S, Nyenhuis S, Solomonides A, Barbarioli B, Bhargava A, Birz S, et al.
J Clin Transl Sci . 2024 Jan; 7(1):e255. PMID: 38229897
Background/objective: Non-clinical aspects of life, such as social, environmental, behavioral, psychological, and economic factors, what we call the sociome, play significant roles in shaping patient health and health outcomes. This...
3.
Arshad A, Blandon C, Carey K, Verhoef P, Jani P, Volchenboum S, et al.
Crit Care Explor . 2022 Oct; 4(10):e0765. PMID: 36248315
Design: Retrospective observational cohort study. Setting: Quaternary care PICU at the University of Chicago. Patients: All children admitted to the PICU between 2012 and 2019. Interventions: None. Measurements And Main...
4.
Mayampurath A, Ajith A, Anderson-Smits C, Chang S, Brouwer E, Johnson J, et al.
J Allergy Clin Immunol Pract . 2022 Sep; 10(11):3002-3007.e5. PMID: 36108921
Background: Primary immunodeficiency diseases (PIDD) are a group of immune-related disorders that have a current median delay of diagnosis between 6 and 9 years. Early diagnosis and treatment of PIDD...
5.
Hettmer S, Linardic C, Kelsey A, Rudzinski E, Vokuhl C, Selfe J, et al.
Eur J Cancer . 2022 Jul; 172:367-386. PMID: 35839732
Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children/adolescents less than 18 years of age with an annual incidence of 1-2/million. Inter/intra-tumour heterogeneity raise challenges in clinical, pathological...
6.
Sokol E, Desai A, Applebaum M, Valteau-Couanet D, Park J, Pearson A, et al.
J Clin Oncol . 2020 Sep; 38(31):3720-3721. PMID: 32931402
No abstract available.
7.
Sokol E, Desai A, Applebaum M, Valteau-Couanet D, Park J, Pearson A, et al.
J Clin Oncol . 2020 Apr; 38(17):1906-1918. PMID: 32315273
Purpose: The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked...
8.
Sokol E, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, et al.
Pediatr Blood Cancer . 2018 Sep; 65(12):e27417. PMID: 30198643
Background: Radiolabeled metaiodobenzylguanidine (MIBG) is sensitive and specific for detecting neuroblastoma. The extent of MIBG-avid disease is assessed using Curie scores. Although Curie scoring is prognostic in patients with high-risk...
9.
Bao R, Hernandez K, Huang L, Kang W, Bartom E, Onel K, et al.
PLoS One . 2015 Aug; 10(8):e0135800. PMID: 26271043
Whole exome sequencing has facilitated the discovery of causal genetic variants associated with human diseases at deep coverage and low cost. In particular, the detection of somatic mutations from tumor/normal...
10.
Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge M, et al.
Br J Haematol . 2015 Apr; 170(1):66-79. PMID: 25824111
Toward our goal of personalized medicine, we comprehensively profiled pre-treatment malignant plasma cells from multiple myeloma patients and prospectively identified pathways predictive of favourable response to bortezomib-based treatment regimens. We...